Ipsen (IPN.PA) and Galderma Laboratories Increase Their Collaboration for Dysport® in New Territories
12/3/2012 11:15:28 AM
PARIS & LAUSANNE, Switzerland--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty-driven pharmaceutical group, and Galderma, a leading global pharmaceutical company focused on dermatology, today announced that their collaboration for the promotion and distribution of Dysport®, Ipsen’s botulinum toxin type A in aesthetic indications, has been extended. Both companies renewed their collaboration in Brazil and Argentina and extended their partnership to Australia where Galderma has the exclusive promotion and distribution rights for Ipsen’s Dysport® in glabellar lines indication. In those territories, Galderma has a unique and complete portfolio of products and services in the Aesthetic & Corrective field, with products such as Restylane®, Emervel® and Pliaglis®. In Brazil, the world’s second largest aesthetic market, Dysport® sales within aesthetics doubled over the initial agreement period (2008-2012).
comments powered by